Third-line treatment for overactive bladder: should mirabegron be tried before intravesical botulinum toxin A therapy?

[1]  Xiaohong Yan,et al.  OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled Trial , 2013, The Journal of urology.

[2]  L. Cardozo,et al.  Mirabegron in overactive bladder: A review of efficacy, safety, and tolerability , 2014, Neurourology and urodynamics.

[3]  J. Corcos,et al.  What do we know and not know about mirabegron, a novel β3 agonist, in the treatment of overactive bladder? , 2014, International Urogynecology Journal.

[4]  G. Amarenco,et al.  A proof‐of‐concept study: Mirabegron, a new therapy for overactive bladder , 2013, Neurourology and urodynamics.

[5]  M. Kvasz,et al.  Health economics perspective of fesoterodine, tolterodine or solifenacin as first-time therapy for overactive bladder syndrome in the primary care setting in Spain , 2013, BMC Urology.

[6]  K. Andersson.  New developments in the management of overactive bladder: focus on mirabegron and onabotulinumtoxinA , 2013, Therapeutics and clinical risk management.

[7]  V. Nitti,et al.  Results of a randomized phase III trial of mirabegron in patients with overactive bladder. , 2013, The Journal of urology.

[8]  O. Yamaguchi,et al.  A phase II dose-ranging study of mirabegron in patients with overactive bladder , 2013, International Urogynecology Journal.

[9]  G. Amarenco,et al.  Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. , 2013, European urology.

[10]  K. Abrams,et al.  Validation of the Patient Global Impression scales for use in detrusor overactivity: secondary analysis of the RELAX study , 2013, BJOG : an international journal of obstetrics and gynaecology.

[11]  P. Dasgupta,et al.  Repeated botulinum toxin type A injections for refractory overactive bladder: medium-term outcomes, safety profile, and discontinuation rates. , 2012, European urology.

[12]  V. Nitti,et al.  885 THE EFFICACY AND SAFETY OF MIRABEGRON IN PATIENTS WITH OVERACTIVE BLADDER SYNDROME – RESULTS FROM A NORTH-AMERICAN PHASE III TRIAL , 2011 .

[13]  A. Rojas,et al.  Reseña de "Updated systematic review and meta-analysis of the comparative data on colposuspensions, pubovaginal slings, and midurethral tapes in the surgical treatment of female stress urinary incontinence" de Novara G, Artibani W, Barber MD et al. , 2011 .

[14]  M. Barber,et al.  Updated systematic review and meta-analysis of the comparative data on colposuspensions, pubovaginal slings, and midurethral tapes in the surgical treatment of female stress urinary incontinence. , 2010, European urology.

[15]  Z. Gabriel,et al.  The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. , 2008, European urology.

[16]  J. Duckett,et al.  Tolerability and efficacy of duloxetine in a nontrial situation. , 2007, BJOG : an international journal of obstetrics and gynaecology.

[17]  Z. Gabriel,et al.  The effects of antimuscarinics on health-related quality of life in overactive bladder: a systematic review and meta-analysis. , 2006, Urology.